VISTA Program Leadership

In his new role, Tendler will lead the clinical development strategy and operations for the company’s VISTA program, including the Phase 2 anti‑VISTA antibody TBS‑2025 for acute myeloid leukemia (AML). The VISTA program is a central focus for TuHURA, and Tendler’s expertise is expected to accelerate its progress toward later‑stage trials. He will also oversee the Phase 3 development of the lead innate‑immune agonist IFx‑2.0, and the pipeline’s novel technologies that target myeloid‑derived suppressor cells to counteract immune suppression within the tumor microenvironment.